On January 8, Zenas BioPharma’s chief executive, Leon Moulder, Jr., acquired an additional 30,000 shares of the company, lifting his direct ownership to 346,155 shares. This transaction, disclosed via a Form 4 filing with the SEC, represents a 9.49% increase in his personal position and brings the total value of his holdings to approximately $5.64 million. Such a sizable insider purchase by the CEO underscores management’s conviction in the company’s clinical pipeline and long-term growth prospects.

Large insider purchases often signal confidence from those with the most in-depth knowledge of the business. Moulder’s latest buy follows earlier acquisitions totaling 70,000 shares over the preceding two trading days, bringing his total outlay to nearly $1.63 million. For investors, this repeated accumulation may heighten interest in Zenas BioPharma’s ongoing oncology and infectious-disease programs, while also drawing attention to upcoming clinical readouts and regulatory milestones that could drive valuation.